BRIEF—Takeda and Ovid Therapeutics expand clinical program for TAK-935/OV935
Under their TAK-935/OV935 program, Japan’s Takeda and USA-based Ovid Therapeutics plan to initiate three clinical trials:
- in pediatric patients with Dravet syndrome and Lennox-Gastaut syndrome;
- in pediatric patients with CDKL5 deficiency disorder (CDD) and Duplication 15q (Dup15q) syndrome; and
- an extension trial for patients with developmental and epileptic encephalopathies (DEEs) who participated in a previous TAK-935/OV935 clinical study.
These trials join the clinical development program that includes a fully enrolled Phase Ib/IIa trial of adults with DEE.
Together, these trials will further investigate the potential of TAK-935/OV935 to modulate the N-Methyl-D-Aspartate (NMDA) signaling receptor, which has been implicated in several neurologic disorders.
“Takeda and Ovid believe that TAK-935/OV935, with its novel mechanism of action, may have the potential to treat rare epilepsies.” said Emiliangelo Ratti, head of the Neuroscience Therapeutic Area Unit at Takeda.
“The expansion of our clinical program to include pediatric populations, and additional rare epilepsies, exemplifies our joint commitment to identify an innovative treatment option for DEE,” he added.
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze